Compass Therapeutics Inc. (CMPX) Financials

Compass Therapeutics (CMPX) financials: revenue, profit and margins

Compass Therapeutics (CMPX) generated about n/a in revenue and -$68 million in net income over the trailing twelve months. Figures are from SEC filings; this is analysis, not investment advice.

Frequently asked

Is Compass Therapeutics profitable?+

Compass Therapeutics reported about -$68 million in net loss over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.

More on CMPX: Overview · Quality scorecard · DCF valuation · Dividend safety

SourceFinancial statements computed from the 10-Q filed 5 May 2026, covering the period ending 31 Mar 2026, as reported to the SEC. Data last refreshed 4 Jun 2026. How this is calculated.

Fiscal year ends Dec.

Loading stock

Related stocks: Biological Products, (No Diagnostic Substances)

EXELExelixis Inc.

AMGNAmgen Inc.

RXRXRecursion Pharmaceuticals, Inc.

SCLXScilex Holding Company

AIMAIM ImmunoTech Inc.

BCDABioCardia, Inc.

PROKProKidney Corp

ELUTElutia Inc.

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.